• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia.

作者信息

Fernando Fiona, Innes Andrew J, Claudiani Simone, Pryce Angharad, Hayden Chloe, Byrne Jenny, Gallipoli Paolo, Copland Mhairi, Apperley Jane F, Milojkovic Dragana

机构信息

Centre for Haematology, Imperial College London, London, UK.

Department of Clinical Haematology, Imperial College Healthcare NHS Trust, London, UK.

出版信息

Bone Marrow Transplant. 2023 Jul;58(7):826-828. doi: 10.1038/s41409-023-01975-9. Epub 2023 Apr 4.

DOI:10.1038/s41409-023-01975-9
PMID:37015970
Abstract
摘要

相似文献

1
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia.移植后阿塞西尼布治疗慢性髓性白血病患者的疗效
Bone Marrow Transplant. 2023 Jul;58(7):826-828. doi: 10.1038/s41409-023-01975-9. Epub 2023 Apr 4.
2
Asciminib as a new option in the treatment of chronic myeloid leukemia.阿塞西尼布作为慢性粒细胞白血病治疗的新选择。
Future Oncol. 2021 Dec;17(36):5003-5005. doi: 10.2217/fon-2021-1174. Epub 2021 Nov 18.
3
Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population.阿伐替尼在真实世界多耐药慢性髓性白血病患者群体中的治疗模式及临床结局
Haematologica. 2023 Jan 1;108(1):240-244. doi: 10.3324/haematol.2022.281386.
4
Asciminib in chronic myeloid leukemia: many questions still remain to be answered.阿伐替尼治疗慢性髓性白血病：仍有许多问题有待解答。
Blood Cancer J. 2021 Apr 29;11(4):81. doi: 10.1038/s41408-021-00475-7.
5
Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.阿斯科利尼布治疗慢性髓性白血病患者在现实临床实践中的安全性和有效性。
Blood Cancer J. 2021 Feb 9;11(2):16. doi: 10.1038/s41408-021-00420-8.
6
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。
N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.
7
Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.澳大利亚接受管理准入计划（MAP）下服用 ASCIMIB 的慢性髓性白血病患者的临床结局。
Intern Med J. 2024 Jul;54(7):1214-1218. doi: 10.1111/imj.16446. Epub 2024 Jun 17.
8
Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting.打破常规：阿伐替尼作为一线慢性髓性白血病治疗武器库中的标准治疗药物。
Future Oncol. 2023 Mar;19(8):545-547. doi: 10.2217/fon-2023-0095. Epub 2023 Apr 11.
9
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.使用阿斯科利尼布和博舒替尼联合抑制BCR-ABL克服慢性髓性白血病患者的TKI耐药性。
Am J Hematol. 2021 Aug 1;96(8):E293-E295. doi: 10.1002/ajh.26231. Epub 2021 May 25.
10
Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia.阿西替尼：一线治疗慢性髓性白血病的新一代子弹。
Med. 2024 Aug 9;5(8):856-858. doi: 10.1016/j.medj.2024.07.001.

引用本文的文献

1
Changes in donor lymphocyte infusion for relapsed patients post-hematopoietic stem cell transplantation: a 30-year single-center experience.造血干细胞移植后复发患者供体淋巴细胞输注的变化：一项30年的单中心经验
Front Immunol. 2025 Jan 29;16:1521895. doi: 10.3389/fimmu.2025.1521895. eCollection 2025.
2
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.BCR::ABL1 单核苷酸变异对 asciminib 疗效的影响。
Leukemia. 2024 Nov;38(11):2443-2455. doi: 10.1038/s41375-024-02411-7. Epub 2024 Sep 17.

本文引用的文献

1
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.一项 3 期、开放标签、随机研究，评估了 STAMP 抑制剂 ASCiminib 与博舒替尼（一种二代 TKI）在 2 种或更多种 TKI 治疗后 CML 患者中的疗效。
Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984.
2
The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era.供体淋巴细胞输注（DLI）在酪氨酸激酶抑制剂（TKI）时代慢性髓性白血病（CML）造血细胞移植（HCT）后复发中的作用
Biol Blood Marrow Transplant. 2020 Jun;26(6):1137-1143. doi: 10.1016/j.bbmt.2020.02.006. Epub 2020 Feb 14.
3
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
阿西替尼在 ABL 激酶抑制剂失败后的慢性髓性白血病中的应用。
N Engl J Med. 2019 Dec 12;381(24):2315-2326. doi: 10.1056/NEJMoa1902328.
4
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.异基因造血干细胞移植治疗慢性粒细胞白血病后维持酪氨酸激酶抑制剂：国际血液和骨髓移植研究中心的一项研究
Biol Blood Marrow Transplant. 2020 Mar;26(3):472-479. doi: 10.1016/j.bbmt.2019.10.017. Epub 2019 Oct 25.
5
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression .新型变构抑制剂阿伐替尼易受ABCB1和ABCG2过表达介导的耐药影响。
Oncotarget. 2018 Feb 3;9(17):13423-13437. doi: 10.18632/oncotarget.24393. eCollection 2018 Mar 2.
6
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.波纳替尼在一名费城染色体阳性急性淋巴细胞白血病且无T315I突变的患者异基因移植后复发时诱导的移植物抗宿主病/移植物抗白血病效应
Chemotherapy. 2017;62(6):353-356. doi: 10.1159/000477714. Epub 2017 Aug 16.
7
Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.波纳替尼在一名异基因移植后早期复发的携带T315I突变的费城染色体阳性急性淋巴细胞白血病患者中诱导出持续的分子反应以及移植物抗宿主病/移植物抗白血病效应。
Chemotherapy. 2017;62(1):58-61. doi: 10.1159/000448750. Epub 2016 Sep 10.
8
Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT.异基因造血干细胞移植治疗慢性髓性白血病分子复发后早期给予供体淋巴细胞输注：欧洲血液与骨髓移植协会慢性恶性肿瘤工作组的一项研究
Haematologica. 2014 Sep;99(9):1492-8. doi: 10.3324/haematol.2013.100198. Epub 2014 Jul 4.
9
Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.异基因造血细胞移植的非清髓预处理治疗高危急性淋巴细胞白血病。
Haematologica. 2011 Aug;96(8):1113-20. doi: 10.3324/haematol.2011.040261. Epub 2011 Apr 20.
10
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.高危费城染色体阳性白血病造血细胞移植后伊马替尼的预防性给药。
Blood. 2007 Apr 1;109(7):2791-3. doi: 10.1182/blood-2006-04-019836.